Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data

Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Caribou Biosciences and keeping the price target at $8.00.

Introducing TipRanks MCP for Agents

• Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
• Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Yigal Nochomovitz has given his Buy rating due to a combination of factors related to Caribou Biosciences’ emerging allo CAR-T portfolio and the strength of new clinical data. At EHA 2026, the company reported extended follow-up for vispa-cel in second-line LBCL showing high overall and complete response rates, now coupled with a median progression-free survival of 17.1 months, while maintaining a safety profile compatible with outpatient use and broader community adoption.

Additionally, CB-011 continued to show deep and durable responses in heavily pre-treated, BCMA-naïve R/R multiple myeloma patients at the selected recommended dose, with high complete response, overall response, and MRD negativity rates and no signal of serious allo-specific toxicities such as GvHD or immune effector cell–associated complications. With a pivotal Phase 3 trial for vispa-cel being prepared, ongoing CB-011 expansion cohorts, and the overall dataset reinforcing the allo CAR-T value proposition, Nochomovitz sees substantial upside potential and keeps his price target unchanged at $8, supporting a Buy rating on this high-risk, high-reward name.

Nochomovitz covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Travere Therapeutics, and ACADIA Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of 7.6% and a 42.34% success rate on recommended stocks.

In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $6.00 price target.